Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA.
Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred.
Shares of Marksans Pharma Limited was last trading in BSE at Rs. 205.65 as compared to the previous close of Rs. 205.45. The total number of shares traded during the day was 136552 in over 2793 trades.
The stock hit an intraday high of Rs. 211.55 and intraday low of 199.95. The net turnover during the day was Rs. 28211016.00. |
